x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012339
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IP |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ile286 of human NDUFS1 protein. Antibodies are purified by peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | NDUFS1 |
| UniProt No. | P28331 |
| Gene ID | 4719 |
| Gene Description | NDUFS1 is a nuclear encoded structural subunit of NADH: ubiquinone oxidoreductase in the mitochondrial electron transport chain. Mutations in NDUFS1 and other complex 1 subunits leading to mitochondrial dysfunction are associated with a number of neurological disorders. High-fat diet associated with type 2 diabetes leads to decreased expression of complex 1 subunits, including NDUFS1. NDUFS1 is the target of cleavage by apoptotic caspases contributing to the loss of mitochondrial transmembrane potential, compromised mitochondrial respiration, increased mitochondrial reactive oxygen species production, and loss of lysosomal integrity. NDUFS1 can also be cleaved by the lymphocyte protease granzyme B. Studies have also found that MDM2, which has a canonical role as an inhibitor of the tumor suppressor p53, can also sequester NDUFS1 in the cytoplasm, leading to respiratory dysfunction and increases in ROS. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
